58 QS-B220 explosives trace detectors to be deployed across Finnish airports.
WILMINGTON, MASS. – Implant Sciences Corporation, a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has sold 58 of its QS-B220 desktop explosives trace detectors to Finnish Airports. The systems are scheduled to be deployed within the next several months.
“The QS-B220 is the only fully developed, globally certified, and deployed non-rad ETD on the market. Customers all across Europe are actively responding to our superior performance and value proposition, as we continue to win tender after tender,” stated Dr. Darryl Jones, Implant Sciences’ Vice President of Sales and Marketing. “We have found that, when we go head to head with our competitors in these EU airport trials, we have been selected as the optimal vendor nearly every time. Clients are seeing that not all non-rad ETD units perform equally, and we are confident that our market penetration will continue throughout the EU.”
“Though not necessarily the lowest-priced unit, our unit’s outstanding performance in the operational trial at the airport led us to being selected over the competition,” added Dr. Bill McGann, Implant Sciences’ CEO. “The QS-B220 is a top-performing unit in the ETD industry. For airports, balancing security with high-throughput is of the utmost importance, and we believe that our unit consistently delivers.”
Tatiana is the news coordinator for TravelDailyNews Media Network (traveldailynews.gr, traveldailynews.com and traveldailynews.asia). Her role includes monitoring the hundreds of news sources of TravelDailyNews Media Network and skimming the most important according to our strategy.
She holds a Bachelor's degree in Communication & Mass Media from Panteion University of Political & Social Studies of Athens and she has been editor and editor-in-chief in various economic magazines and newspapers.
